See the latest NICE Ltd ADR stock price (NICE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

NICE technology appraisals for cancer drugs are often delayed - but who's really to blame? This post investigates how the DHSC contributes to hold-ups in access to innovative cancer treatments.

NICE rejects AstraZeneca and Daiichi Sankyo’s Enhertu for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.